Literature DB >> 16829076

Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.

Thomas van Groen1, Amanda J Kiliaan, Inga Kadish.   

Abstract

The deposition of amyloid beta (Abeta) peptides and neurofibrillary tangles are the two characteristic pathological features of Alzheimer's disease (AD). To investigate the relation between amyloid precursor protein (APP) production, amyloid beta deposition and the type of Abeta in deposits, i.e., human and/or mouse, we performed a histopathological analysis, using mouse and human specific antibodies, of the neocortex and hippocampus in 6, 12 and 19 months old APP/PS1 double and APP and PS1 single transgenic mice. There was a significant correlation between the human amyloid beta deposits and the intrinsic rodent amyloid beta deposits, that is, all plaques contained both human and mouse Abeta, and the diffuse amyloid beta deposits also colocalized human and mouse Abeta. Furthermore, some blood vessels (mainly leptomeningeal vessels) show labeling with human Abeta, and most of these vessels also label with mouse Abeta. Our findings demonstrate that the human amyloid deposits in APP/PS1 transgenic mice are closely associated with mouse Abeta, however, they do not precisely overlap. For instance, the core of plaques consists of primarily human Abeta, whereas the rim of the plaque contains both human and mouse amyloid beta, similarly, human and mouse Abeta are differentially localized in the blood vessel wall. Finally, as early as amyloid beta deposits can be detected, they show the presence of both human and mouse Abeta. Together, these data indicate that mouse Abeta is formed and deposited in significant amounts in the AD mouse brain and that it is deposited together with the human Abeta.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16829076     DOI: 10.1016/j.nbd.2006.05.010

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  39 in total

1.  Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid β-peptide deposition: insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer's disease.

Authors:  Renã A S Robinson; Gururaj Joshi; Quanzhen Huang; Rukhsana Sultana; Austin S Baker; Jian Cai; William Pierce; Daret K St Clair; William R Markesbery; D Allan Butterfield
Journal:  Proteomics       Date:  2011-09-22       Impact factor: 3.984

2.  Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's Disease transgenic mice.

Authors:  Susanne Aileen Funke; Thomas van Groen; Inga Kadish; Dirk Bartnik; Luitgard Nagel-Steger; Oleksandr Brener; Torsten Sehl; Renu Batra-Safferling; Christine Moriscot; Guy Schoehn; Anselm H C Horn; Andreas Müller-Schiffmann; Carsten Korth; Heinrich Sticht; Dieter Willbold
Journal:  ACS Chem Neurosci       Date:  2010-08-02       Impact factor: 4.418

3.  Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice.

Authors:  Huang Huang; Sipei Nie; Min Cao; Charles Marshall; Junying Gao; Na Xiao; Gang Hu; Ming Xiao
Journal:  Age (Dordr)       Date:  2016-07-21

4.  A Novel 1,4-Dihydropyridine Derivative Improves Spatial Learning and Memory and Modifies Brain Protein Expression in Wild Type and Transgenic APPSweDI Mice.

Authors:  Baiba Jansone; Inga Kadish; Thomas van Groen; Ulrika Beitnere; Doyle Ray Moore; Aiva Plotniece; Karlis Pajuste; Vija Klusa
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

5.  Thiacremonone Potentiates Anti-Oxidant Effects to Improve Memory Dysfunction in an APP/PS1 Transgenic Mice Model.

Authors:  Hyung-Mun Yun; Peng Jin; Kyung-Ran Park; JaeRyun Hwang; Heon-Sang Jeong; Eun-Cheol Kim; Jea-Kyung Jung; Ki-Wan Oh; Bang Yeon Hwang; Sang Bae Han; Jin Tae Hong
Journal:  Mol Neurobiol       Date:  2015-05-26       Impact factor: 5.590

6.  Treatment with D3 removes amyloid deposits, reduces inflammation, and improves cognition in aged AβPP/PS1 double transgenic mice.

Authors:  Thomas van Groen; Inga Kadish; Susanne Aileen Funke; Dirk Bartnik; Dieter Willbold
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

7.  Endogenous murine Aβ increases amyloid deposition in APP23 but not in APPPS1 transgenic mice.

Authors:  Jasmin Mahler; Jose Morales-Corraliza; Julia Stolz; Angelos Skodras; Rebecca Radde; Carmen C Duma; Yvonne S Eisele; Matthew J Mazzella; Harrison Wong; William E Klunk; K Peter R Nilsson; Matthias Staufenbiel; Paul M Mathews; Mathias Jucker; Bettina M Wegenast-Braun
Journal:  Neurobiol Aging       Date:  2015-03-25       Impact factor: 4.673

Review 8.  Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of central nervous system diseases.

Authors:  Da-Zhi Liu; Bradley P Ander; Frank R Sharp
Journal:  Neurobiol Dis       Date:  2009-11-24       Impact factor: 5.996

9.  Memory-enhancing and brain protein expression-stimulating effects of novel calcium antagonist in Alzheimer's disease transgenic female mice.

Authors:  Baiba Jansone; Inga Kadish; Thomas van Groen; Ulrika Beitnere; Aiva Plotniece; Karlis Pajuste; Vija Klusa
Journal:  Pharmacol Res       Date:  2016-06-21       Impact factor: 7.658

10.  MRI and histological analysis of beta-amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice.

Authors:  Mark D Meadowcroft; James R Connor; Michael B Smith; Qing X Yang
Journal:  J Magn Reson Imaging       Date:  2009-05       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.